摘要
结直肠癌实质性器官转移中最常见的部位是肝脏,在诊疗过程中超过一半的结直肠癌患者都会发生肝转移。结直肠癌是否发生肝转移极大的影响了临床决策并直接决定了患者的预后。尽管化疗、手术的生存率有所提高,但将肝转移灶完整的切除是结直肠癌肝转移患者获得潜在治愈的唯一机会,多数证据表明外科手术具有显著的生存效益。转移灶肝切除术后的5年生存率可达到35%~55%。遗憾的是,只有10%~20%的患者被认为有资格进行手术切除。因此,运用转化治疗将初始不可切除的CRLM转化为可切除CRLM,从而提高m CRC患者的手术切除率、延长生存时期和改善预后,是当前的研究热点。本文就转化治疗(conversion therapy)中转化化疗的内涵、转化方法、研究进展进行综述。
Liver metastasis is the most common site of colorectal cancer metastasis. More than half of all colorectal cancer patients will develop liver metastases. Whether colorectal cancer has liver metastasis has great impact on clinical decisionmaking and directly determines the prognosis of patients. Although radical surgery is the standard treatment modality,only10 ~ 20% of patients are deemed eligible for resection. Despite advances in survival with chemotherapy,surgical resection is still considered the only curative option for patients with liver metastases. The majority of evidence stated a significant survival benefit with surgical resection to reach an overall 5-year survival rate of 35% ~ 55% after hepatic resection. thus improving the surgical resection rate,prolonging the survival time and improving the prognosis of m CRC patients. In this review,we describe the connotation,transformation methods and research progress of conversion chemotherapy in conversion therapy.
作者
乔鋆
张睿
Yun Qiao;Rui Zhang(Department of Colorectal Surgery, Cancer Hospital of China Medical University/Liaoning Cancer Hospita)
出处
《辽宁医学杂志》
2018年第3期11-14,共4页
Medical Journal of Liaoning
关键词
转化治疗
靶向药物
联合化疗
二线转化
Conversion therapy
Targeted drugs
Combination chemotherapy
Second line conversion